All Pharma News
InxMed Enters License Agreement with Escugen to Develop Next-Generation ADCs

InxMed Enters License Agreement with Escugen to Develop Next-Generation ADCs
PR NEWSWIRE
19 Dec 2023
Share Share
InxMed Releases Data Demonstrating Ifebemtinib Trending Toward Survival Benefit

InxMed Releases Data Demonstrating Ifebemtinib Trending Toward Survival Benefit
PR NEWSWIRE
22 Oct 2023
Share Share
InxMed Presents Data at 14th World ADC Highlighting Synergy of IN10018

InxMed Presents Data at 14th World ADC Highlighting Synergy of IN10018
PR NEWSWIRE
18 Oct 2023
Share Share
InxMed Receives Approval PhI Trial China for OMTX705, a 1st-in-Class FAP ADC

InxMed Receives Approval PhI Trial China for OMTX705, a 1st-in-Class FAP ADC
PR NEWSWIRE
29 Aug 2023
Share Share
GeneQuantum and InxMed have reached a technology licensing collaboration

GeneQuantum and InxMed have reached a technology licensing collaboration
PR NEWSWIRE
17 Jul 2023
Share Share
InxMed IN10018 at ASCO 2022 demonstrates robust efficacy in ovarian cancer

InxMed IN10018 at ASCO 2022 demonstrates robust efficacy in ovarian cancer
PRNEWSWIRE
29 May 2022
Share Share
InxMed Raised $15M in Series B+ Financing

InxMed Raised $15M in Series B+ Financing
FINSMES
09 May 2022
Share Share
InxMed Raised $15M in Series B+ Financing

InxMed Raised $15M in Series B+ Financing
PRNEWSWIRE
08 May 2022
Share Share
InxMed FAK Inhibitor IN10018 Received BTD by NMPA

InxMed FAK Inhibitor IN10018 Received BTD by NMPA
PRNEWSWIRE
13 Apr 2022
Share Share
US FDA grants fast track designation to InxMed`s IN10018

US FDA grants fast track designation to InxMed`s IN10018
PHARMABIZ
16 Aug 2021
Share Share